Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Jung-Tung Hung"'
Autor:
Tsai-Hsien Hung, Yenlin Huang, Chau-Ting Yeh, Chun-Nan Yeh, John Yu, Chun-Cheng Lin, Shih-Pin Chiou, Pei-Yun Chiang, Jung-Tung Hung, Alice L. Yu
Publikováno v:
Biomedical Journal, Vol 47, Iss 2, Pp 100612- (2024)
Background: Malignant cells may arise from dedifferentiation of mature cells and acquire features of the progenitor cells. Definitive endoderm from which liver is derived, expresses glycosphingolipids (GSLs) such as stage-specific embryonic antigen 3
Externí odkaz:
https://doaj.org/article/5377dd55055e4bf2991993ed61ddafe4
Autor:
Sheng-Hung Wang, Jing-Yan Cheng, Hsiu-Hui Tsai, Tzu-Chi Lo, Jung-Tung Hung, Chun-Cheng Lin, Chien-Wei Lee, Yi-Hsuan Ho, Huan-Hsien Kuo, Alice L. Yu, John Yu
Publikováno v:
Journal of Biomedical Science, Vol 29, Iss 1, Pp 1-18 (2022)
Abstract Background In endothelial cells, phospholipase C (PLC) β1-activated Ca2+ is a crucial second messenger for the signaling pathways governing angiogenesis. PLCβ1 is inactivated by complexing with an intracellular protein called translin-asso
Externí odkaz:
https://doaj.org/article/02741782cf294cdcab418047b7ad9299
Autor:
Rajen Mody, KyungMann Kim, Paul M Sondel, Amy K Erbe, Julie Park, Sabah Servaes, Jen Birstler, Wendy B London, Jung-Tung Hung, Alice L Yu, John M Maris, Mitch B Diccianni, Arlene Naranjo, Fan F Zhang, Arika S Feils, Barry L Shulkin, Varsha Mathew, Marguerite T Parisi, Shahab Asgharzadeh, Rochelle Bagatell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background In the Children’s Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy
Externí odkaz:
https://doaj.org/article/443a5adb348f4ea680fa7f58633c74ff
Autor:
Tsai‐Hsien Hung, Jung‐Tung Hung, Chiao‐En Wu, Yenlin Huang, Chien‐Wei Lee, Chau‐Ting Yeh, Yi‐Hsiu Chung, Fei‐Yun Lo, Li‐Chun Lai, John K. Tung, John Yu, Chun‐Nan Yeh, Alice L. Yu
Publikováno v:
Hepatology Communications, Vol 6, Iss 1, Pp 194-208 (2022)
Recent studies support the development of cancer therapeutics to target Globo H‐ceramide, the most prevalent tumor‐associated carbohydrate antigen in epithelial cancers. Herein, we evaluated the expression of Globo H and its prognostic significan
Externí odkaz:
https://doaj.org/article/e49b3e59fb7343d799fb3ad7b081eafa
Autor:
Michael J Campbell, Hope S Rugo, Chiun-Sheng Huang, Chun-Yen Lin, Jung-Tung Hung, I-Ju Chen, Shir-Hwa Ueng, Shin-Cheh Chen, Mu-Yi Chen, Yung-Chang Lin, Alice L Yu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/89c1a2bb641f4bd6abe6049e9723de97
Autor:
Yu-Mei Liao, Ya-Hui Wang, Jung-Tung Hung, Yu-Ju Lin, Yen-Lin Huang, Guo-Shiou Liao, Ya-Ling Hsu, Jen-Chien Wu, Alice L. Yu
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Existence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BCSCs. However, little
Externí odkaz:
https://doaj.org/article/8c35b3de1c284ef08fb19ff4b1f14d53
Autor:
Yeng-Nan Chen, Jung-Tung Hung, Fan-Dan Jan, Yung-Yu Su, Jih-Ru Hwu, Alice L. Yu, Avijit K. Adak, Chun-Cheng Lin
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 21, p 13403 (2022)
Structural variants of α-galactosylceramide (α-GalCer) that stimulate invariant natural killer T (iNKT) cells constitute an emerging class of immunomodulatory agents in development for numerous biological applications. Variations in lipid chain len
Externí odkaz:
https://doaj.org/article/cfc43b7362be4730923e4fb9948c5a52
Autor:
Jing-Yan Cheng, Jung-Tung Hung, Juway Lin, Fei-Yun Lo, Jing-Rong Huang, Shih-Pin Chiou, Ya-Hui Wang, Ruey-Jen Lin, Jen-Chine Wu, John Yu, Alice L. Yu
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
SynopsisA sugar-lipid molecule called OAcGD2 is a novel marker for breast cancer stem cells. Treatment with anti-OAcGD2 mAb8B6 may have superior anticancer efficacy by targeting cancer stem cells, thereby reducing metastasis and recurrence of cancer.
Externí odkaz:
https://doaj.org/article/4b03ab46f4d44c989167a41cc5133d15
Autor:
Sung-Bae Kim, Hope S Rugo, Sara A Hurvitz, Hong-Tai Chang, Chiun-Sheng Huang, Su-Hua Lee, Jung-Tung Hung, Shir-Hwa Ueng, Shin-Cheh Chen, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Richard B Schwab, James L Murray, Hsien-Kun Chang, Chwen-Cheng Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821
Externí odkaz:
https://doaj.org/article/6edfc74c39b5454884784f7a49c0a626
Autor:
Yu-Mei Liao, Tsai-Hsien Hung, John K. Tung, John Yu, Ya-Ling Hsu, Jung-Tung Hung, Alice L. Yu
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 2, p 122 (2021)
Immune tumor microenvironment (TME) in neuroblastoma (NBL) contributes to tumor behavior and treatment response. T cells and natural killer (NK) cells have been shown to play important roles in the neuroblastoma TME. However, few reports address the
Externí odkaz:
https://doaj.org/article/3b1d63539c434a54bf3d9b57ca0cd72e